Fadi Mansour

Learn More
Implantable cardioverter-defibrillators (ICDs) improve survival when used as primary or secondary prevention therapy in patients with a broad spectrum of disorders associated with a high risk of sudden death. As indications continue to be refined, attention has increasingly turned to ICD-related complications and their impact on quality of life. Foremost(More)
BACKGROUND Optimization of atrioventricular (AV) and interventricular (VV) intervals may improve cardiac resynchronization therapy (CRT) response but is a complex task. Fusion with intrinsic conduction may increase the benefit of CRT. The aim was to describe fusion-optimized intervals (FOI), a new method of optimizing CRT based on QRS duration. METHODS(More)
Ventricular tachycardia episodes terminating during or immediately after device charging are not expected to be treated by current implantable cardioverter defibrillators as shocks are non-committed. For proper troubleshooting, the reconfirmation algorithm will be reviewed.
Implantable cardioverter-defibrillators (ICD) are widely regarded as the treatment of choice for primary and secondary prevention against sudden cardiac death across a broad spectrum of underlying pathologies. Over the past 20 years, ICDs have evolved into complex multifunctional units capable of recording, chronicling, self-testing, and delivering(More)
A 36 year-old man with hypertrophic cardiomyopathy and an ATLAS + DR implantable cardioverter defibrillator (ICD) (St. Jude Medical, Inc., St. Paul, MN, USA) for primary prevention received a shock while cycling. The ventricular fibrillation detection threshold was 182 beats/min. An additional monitoring zone was programmed to 156 beats/min with all(More)